NCT07774611
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 28 words
- Start date changed from estimate of Sep 22, 2026 to Sep 18, 2026
- Interventions: SG1827 (Drug), anti-PD-1/PD-L1 antibody (Drug), bevacizumab (Drug) to SG1827 (Drug), anti-PD-1/PD-L1 antibody (Drug), bevacizumab (Drug)
- Site details revised at 10 of 10 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
AEs
Timeframe: From first dose until 30 days after last dose of SG1827
Arms and interventions
SG1827Experimental
Part A employs a Bayesian Optimal Interval (BOIN) design for dose escalation, with six dose levels of SG1827 (0.3, 1, 3, 6, 10, and 15 mg/kg), starting at 0.3 mg/kg and escalating sequentially from low to high. In Part B, the starting dose of SG1827 in combination with an anti-PD-1/PD-L1 antibody and bevacizumab will be determined by the SMC based on available results from Part A, using a dose-finding strategy that includes a safety run-in cohort followed by adaptive dose de-escalation.
Drugs: SG1827, anti-PD-1/PD-L1 antibody, bevacizumab
Sites
10 sites in 1 country